Comprehensive viral screening panel.
Ended Awarded Last action
- Contract number
- 75N93025F00001
- Awardee
-
University Of Alabama At Birmingham UEI YND4PLMC9AN7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $369,399
Award facts
- Contract value 66% obligated
-
- $369,399.00 Current, with exercised options
- $560,418.16 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Birmingham, AL 35294, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $369,399 |
About this award
The National Institute of Allergy and Infectious Diseases awarded a delivery order valued at $560,418.16 to the University of Alabama at Birmingham (UAB) on December 16, 2024, for a Comprehensive Viral Screening Panel. This firm fixed-price delivery order is structured under the In Vitro Assessments of Antimicrobial Activity (IVAAA) master Indefinite Delivery/Indefinite Quantity (IDIQ) contract and does not utilize any set-aside designation. The work will be performed in Birmingham, Alabama, with an ultimate completion date of December 15, 2025. As a comprehensive research university with extensive biomedical research capabilities and a strong federal contract portfolio, UAB is well-positioned to deliver sophisticated viral screening services that support NIAID's infectious disease research and diagnostic objectives.
The delivery order aligns with NIAID's mission to support research on infectious diseases and antimicrobial resistance through advanced in vitro assessment tools. UAB's selection reflects the university's demonstrated expertise in infectious disease research, clinical laboratory services, and its established experience as a critical partner with the National Institutes of Health and other federal research agencies. The Comprehensive Viral Screening Panel will likely support the agency's broader efforts to develop diagnostic capabilities and advance understanding of viral pathogens relevant to public health preparedness and treatment development.
Quick answers
Who was awarded contract 75N93025F00001?
75N93025F00001 was awarded to University Of Alabama At Birmingham by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on December 16, 2024.
How much is contract 75N93025F00001 worth?
The government has obligated $369,399 on 75N93025F00001. Its potential value, with all options, is $560,418.
Is contract 75N93025F00001 an order under another contract?
Yes. 75N93025F00001 is a delivery order under 75N93019D00016, an indefinite delivery contract, on In Vitro Assessments of Antimicrobial Activity (IVAAA).
Was contract 75N93025F00001 competed?
The extent of competition for 75N93025F00001 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award